PRESS RELEASE published on 04/15/2024 at 14:01, 1 year 7 months ago Original-Research: Apontis Pharma AG (von Montega AG): Kaufen Montega AG stuft Apontis Pharma AG hoch und aktualisiert das Kursziel auf 16,50 EUR aufgrund neuer Vertriebsstrategie und Kooperation mit Novartis. Analyst Tim Kruse empfiehlt Kauf Montega AG APONTIS PHARMA AG Kursziel 16,50 EUR Vertriebsstrategie Kooperation Novartis
BRIEF published on 04/05/2024 at 10:22, 1 year 8 months ago APONTIS PHARMA Secures Five-Year Distribution and Marketing Deal with Novartis for Asthma Medications Pharmaceutical Industry Financial Forecast APONTIS PHARMA Asthma Medications Novartis
BRIEF published on 04/05/2024 at 10:22, 1 year 8 months ago APONTIS PHARMA conclut un accord de distribution et de commercialisation de cinq ans avec Novartis pour des médicaments contre l'asthme Prévisions Financières Industrie Pharmaceutique PHARMA APONTIS Médicaments Contre L'asthme Novartis
PRESS RELEASE published on 04/05/2024 at 10:17, 1 year 8 months ago APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast APONTIS PHARMA partners with Novartis for asthma medications distribution and marketing, raising forecast for 2024 financial year Distribution Agreement APONTIS PHARMA Asthma Medications Novartis Forecast Increase
BRIEF published on 04/05/2024 at 10:15, 1 year 8 months ago APONTIS PHARMA AG Enhances Forecast Following Agreement with Novartis APONTIS PHARMA AG Financial Growth Forecast Upgrade Novartis Agreement Asthma Medications
BRIEF published on 04/05/2024 at 10:15, 1 year 8 months ago APONTIS PHARMA AG améliore ses prévisions suite à un accord avec Novartis Croissance Financière APONTIS PHARMA AG Mise À Niveau Des Prévisions Accord Novartis Médicaments Contre L'asthme
PRESS RELEASE published on 04/05/2024 at 10:10, 1 year 8 months ago EQS-Adhoc: APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications APONTIS PHARMA AG raises forecast following agreement with Novartis for asthma medications Forecast Raise Financial Outlook APONTIS PHARMA AG Novartis Agreement Asthma Medications
BRIEF published on 03/28/2024 at 07:35, 1 year 8 months ago APONTIS PHARMA Anticipates Profitable Growth in 2024 After Restructuring APONTIS PHARMA Single Pill Combinations Financial Results 2023 Profitable Growth 2024 Restructuring Program
BRIEF published on 03/28/2024 at 07:35, 1 year 8 months ago APONTIS PHARMA prévoit une croissance rentable en 2024 après sa restructuration Résultats Financiers 2023 PHARMA APONTIS Croissance Rentable 2024 Combinaisons De Pilules Uniques Programme De Restructuration
PRESS RELEASE published on 03/28/2024 at 07:30, 1 year 8 months ago APONTIS PHARMA expects profitable growth again in 2024 APONTIS PHARMA expects profitable growth in 2024 with sales forecasted to rise to EUR 41.7 million and positive EBITDA of EUR 1.8 million. Performance and efficiency improvements drive future growth EBITDA Profitable Growth APONTIS PHARMA Sales Forecast Efficiency Improvements
Published on 12/05/2025 at 20:25, 44 minutes ago The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others
Published on 12/05/2025 at 20:15, 54 minutes ago When Proof Becomes Infrastructure, Markets Rewrite the Story (NASDAQ: SMX)
Published on 12/05/2025 at 19:50, 1 hour 19 minutes ago Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 1 hour 49 minutes ago The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 2 hours 24 minutes ago Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:58, 2 hours 11 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 2 hours 54 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:46, 3 hours 23 minutes ago Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:18, 3 hours 51 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 3 hours 51 minutes ago The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 5 hours 58 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 5 hours 58 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 7 hours 11 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
